Biotechnology
Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
Explore our sectors
Meet our lawyers
News and insights
Blog Post: 03 April 2024
European Commission opens unprecedented abuse of dominance probe in animal medicines sector
The European Commission (EC) has opened a formal antitrust investigation into whether animal health company Zoetis has breached EU antitrust law by preventing the market launch of a competing novel…
Blog Post: 28 March 2024
The English High Court has upheld one of the Czech Republic’s challenges to an investment treaty award won by investors in a blood plasma business after finding that an UNCITRAL tribunal had failed to…
Blog Post: 17 July 2023
When is the composition of a product on the market prior art?
G1/23 – EPO Enlarged Board of Appeals of the EPO “available” (referral from T 0438/19) Under which circumstances can the public prior use of a product constitute prior art for novelty or inventive…
Blog Post: 04 May 2023
Podcast: Scaling up science - how to grow your life sciences venture
How and when do life sciences entrepreneurs decide whether to raise more funds, partner with big pharma, or exit their company? What strategies and tactics do they apply? And what are the key lessons…